Guggenheim Capital LLC Buys 57,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Guggenheim Capital LLC boosted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 528.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,778 shares of the biotechnology company's stock after acquiring an additional 57,000 shares during the quarter. Guggenheim Capital LLC's holdings in ADMA Biologics were worth $1,162,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ADMA. Barclays PLC lifted its position in shares of ADMA Biologics by 192.2% in the 3rd quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock worth $10,567,000 after purchasing an additional 347,692 shares during the period. Franklin Resources Inc. lifted its position in shares of ADMA Biologics by 19.4% in the 3rd quarter. Franklin Resources Inc. now owns 167,644 shares of the biotechnology company's stock worth $3,351,000 after purchasing an additional 27,180 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $368,000. Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $61,858,000. Finally, Principal Financial Group Inc. lifted its position in shares of ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after acquiring an additional 1,059,394 shares during the period. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Up 12.1 %

Shares of NASDAQ ADMA traded up $2.65 during trading on Monday, hitting $24.51. The stock had a trading volume of 10,253,257 shares, compared to its average volume of 3,671,345. ADMA Biologics, Inc. has a 12 month low of $6.49 and a 12 month high of $25.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a market capitalization of $5.82 billion, a PE ratio of 87.54 and a beta of 0.53. The firm has a fifty day moving average of $18.97 and a two-hundred day moving average of $18.33.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.